RU 28965 IN SUPERFICIAL PYOGENIC DISEASES

The authors investigated the clinical effect, bacteriological effect, side-effects and utility of a new macrolide, RU 28965, in 20 patients with superficial pyogenic diseases. The results are presented here. RU 28965 was administered twice daily before morning and evening meals at 200-400mg for 3-15...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 36; no. Supplement4; pp. 534 - 537
Main Authors SOMA, YOSHINAO, OGAWA, KIMIKO, YUN, KOICHI, YUN, SHUKUKA, HARADA, SHOTARO
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1988
公益社団法人 日本化学療法学会
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.36.Supplement4_534

Cover

Abstract The authors investigated the clinical effect, bacteriological effect, side-effects and utility of a new macrolide, RU 28965, in 20 patients with superficial pyogenic diseases. The results are presented here. RU 28965 was administered twice daily before morning and evening meals at 200-400mg for 3-15 consecutive days. The final general improvement was evaluated the day after the initial administration. Clinical effect in 19 patients (excluding one who did not return to the hospital after the administration) was: complete cure 16, remarkable improvement 1, and mild improvement 2. The efficacy rate (mild improvement or better) was 100%. Most of the isolates were staphylococci, and the disappearance rate of bacteria was 86.7%. As side-effects of the drug, angular stomatitis was observed in one case. Since this was mild and did not require treatment, the regimen was continued. As to utility of the drug, it was extremely useful in 14 cases, useful in 3, fairly useful in 1 and not useful in 1 case, with a utility rate of 89.5%.
AbstractList The authors investigated the clinical effect, bacteriological effect, side-effects and utility of a new macrolide, RU 28965, in 20 patients with superficial pyogenic diseases. The results are presented here. RU 28965 was administered twice daily before morning and evening meals at 200-400mg for 3-15 consecutive days. The final general improvement was evaluated the day after the initial administration. Clinical effect in 19 patients (excluding one who did not return to the hospital after the administration) was: complete cure 16, remarkable improvement 1, and mild improvement 2. The efficacy rate (mild improvement or better) was 100%. Most of the isolates were staphylococci, and the disappearance rate of bacteria was 86.7%. As side-effects of the drug, angular stomatitis was observed in one case. Since this was mild and did not require treatment, the regimen was continued. As to utility of the drug, it was extremely useful in 14 cases, useful in 3, fairly useful in 1 and not useful in 1 case, with a utility rate of 89.5%.
The authors investigated the clinical effect, bacteriological effect, side-effects and utility of a new macrolide, RU 28965, in 20 patients with superficial pyogenic diseases. The results are presented here.RU 28965 was administered twice daily before morning and evening meals at 200-400mg for 3-15 consecutive days. The final general improvement was evaluated the day after the initial administration.Clinical effect in 19 patients (excluding one who did not return to the hospital after the administration) was: complete cure 16, remarkable improvement 1, and mild improvement 2. The efficacy rate (mild improvement or better) was 100%. Most of the isolates were staphylococci, and the disappearance rate of bacteria was 86.7%. As side-effects of the drug, angular stomatitis was observed in one case. Since this was mild and did not require treatment, the regimen was continued. As to utility of the drug, it was extremely useful in 14 cases, useful in 3, fairly useful in 1 and not useful in 1 case, with a utility rate of 89.5%. 新しいマクロライド系抗生物質RU 28965を浅在性化膿性疾患患者20例に投与し, その臨床効果, 細菌学的効果, 副作用, 有用性を検討した。投与方法は1日2回, 朝・夕食前に投与し, 投与量は1日200-400mg, 投与日数は3-15日である。投与終了時に最終の全般改善度を判定した。投与後来院しなかった1例を除く19例に対する臨床効果は, 治癒16例, 著しく改善1例, かなり改善2例で, かなり改善以上の有効率は100%であった。病巣分離菌はStaphylococcus属が大部分であった。細菌の消失率は86.7%であった。副作用は1例に口角炎が認められたが軽症であり, 特に処置は行わず投与は継続した。有用性はきわめて有用14例, 有用3例, やや有用1例, 有用とは思われない1例で, 有用率は89.5%であった。
Author HARADA, SHOTARO
YUN, SHUKUKA
YUN, KOICHI
SOMA, YOSHINAO
OGAWA, KIMIKO
Author_FL 小川 喜美子
原田 昭太郎
尹 淑香
相馬 良直
尹 弘一
Author_FL_xml – sequence: 1
  fullname: 原田 昭太郎
– sequence: 2
  fullname: 小川 喜美子
– sequence: 3
  fullname: 尹 淑香
– sequence: 4
  fullname: 尹 弘一
– sequence: 5
  fullname: 相馬 良直
Author_xml – sequence: 1
  fullname: SOMA, YOSHINAO
  organization: Department of Dermatology, Kanto Teishin Hospital
– sequence: 1
  fullname: OGAWA, KIMIKO
  organization: Department of Dermatology, Kanto Teishin Hospital
– sequence: 1
  fullname: YUN, KOICHI
  organization: Department of Dermatology, Kanto Teishin Hospital
– sequence: 1
  fullname: YUN, SHUKUKA
  organization: Department of Dermatology, Kanto Teishin Hospital
– sequence: 1
  fullname: HARADA, SHOTARO
  organization: Department of Dermatology, Kanto Teishin Hospital
BackLink https://cir.nii.ac.jp/crid/1390001206286847360$$DView record in CiNii
BookMark eNpdkE9rwkAQxZdiodb6HXLopdDYnf3n7lHSaAOiYuqhp-12M6kRjSGJB799FXsQL_MYeG-Y93sknXJfIiGvQAcATNI3v8bdvl1j7aojGMkHXA3SQ1VtcYdlK6zk4o50QWsRSm1Eh3QppSbkoOQD6TdN8UMpAFVMsy55Wa4Cpo2SQTIL0tUiXo6TKBlNg8XXfBLPkih4T9J4lMbpE7nP3bbB_r_2yGocf0Yf4XQ-SaLRNNwwIduQGTACpcecCibBGNBUM-qZwQwcB-czyDMUTngAw5UaaiUFy4de55nKFO-R58vdsiisL84TuDlVAHb-WWkx5IqebN8X26Zp3S_aqi52rj5aV7eF36K9pWS5steUbtYTtKuoqy2W_A8Du2r6
ContentType Journal Article
Copyright Japanese Society of Chemotherapy
Copyright_xml – notice: Japanese Society of Chemotherapy
DBID RYH
DOI 10.11250/chemotherapy1953.36.Supplement4_534
DatabaseName CiNii Complete
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate 浅在性化膿性疾患に対するRU 28965の臨床的検討
DocumentTitle_FL 浅在性化膿性疾患に対するRU 28965の臨床的検討
EISSN 1884-5894
EndPage 537
ExternalDocumentID 130004196348
article_chemotherapy1953_36_Supplement4_36_Supplement4_534_article_char_en
GroupedDBID 53G
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
JSF
JSH
KQ8
RJT
RZJ
ZOHVM
RYH
ID FETCH-LOGICAL-j245t-29194e5cef0425199180820c29ed1a31acd1fde4a4c119366786542f7c8fd6d63
ISSN 0009-3165
IngestDate Thu Jun 26 21:32:12 EDT 2025
Wed Sep 03 06:30:12 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue Supplement4
Language English
Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j245t-29194e5cef0425199180820c29ed1a31acd1fde4a4c119366786542f7c8fd6d63
OpenAccessLink https://www.jstage.jst.go.jp/article/chemotherapy1953/36/Supplement4/36_Supplement4_534/_article/-char/en
PageCount 4
ParticipantIDs nii_cinii_1390001206286847360
jstage_primary_article_chemotherapy1953_36_Supplement4_36_Supplement4_534_article_char_en
PublicationCentury 1900
PublicationDate 1988-00-00
PublicationDateYYYYMMDD 1988-01-01
PublicationDate_xml – year: 1988
  text: 1988-00-00
PublicationDecade 1980
PublicationTitle CHEMOTHERAPY
PublicationTitleAlternate Chemother.
PublicationTitle_FL ＣＨＥＭＯＴＨＥＲＡＰＹ
Chemother
PublicationYear 1988
Publisher Japanese Society of Chemotherapy
公益社団法人 日本化学療法学会
Publisher_xml – name: Japanese Society of Chemotherapy
– name: 公益社団法人 日本化学療法学会
References 1) 第35回日本化学療法学会総会, 新薬シンポジウムIV. RU 28965, 盛岡, 1987
References_xml – reference: 1) 第35回日本化学療法学会総会, 新薬シンポジウムIV. RU 28965, 盛岡, 1987
SSID ssib001106282
ssj0000626693
ssib058492509
ssib005879733
ssib008506721
Score 1.1985648
Snippet The authors investigated the clinical effect, bacteriological effect, side-effects and utility of a new macrolide, RU 28965, in 20 patients with superficial...
SourceID nii
jstage
SourceType Publisher
StartPage 534
Title RU 28965 IN SUPERFICIAL PYOGENIC DISEASES
URI https://www.jstage.jst.go.jp/article/chemotherapy1953/36/Supplement4/36_Supplement4_534/_article/-char/en
https://cir.nii.ac.jp/crid/1390001206286847360
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX CHEMOTHERAPY, 1988/09/25, Vol.36(Supplement4), pp.534-537
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 19941231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: KQ8
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 20041231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: DIK
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Bb9MwFLa6ISEuCASIjQ3lwAWVlDpxHPsYlWwJoU3VNGI9RantSq1EmabuAL-HH8pznKRZtcNAcLESR3b7_L28fu_Vfg-hd0IBrxBC2fAyMVunQLe5S5hdOr5QuMRUSR3QH09olJPPV95Vr_ers2vpdrcciJ_3niv5G1ShD3DVp2T_ANl2UuiAa8AXWkAY2gdhPMv74MlQrx9P-lk-DWcX8SgOvvSni_QynMD6foqzMMhqwtfkI4jCcTqPwlkwbWlslo6DyhinOnwVpG3o9TL4Wj1IwMYlbfcirzYHJGk8iuKDzizKkzwJ9tEEzE1FPWPj4bdZ17xsd4tWu0HUt_oc2I87RpSD6TYlHgbK2E3GiO0xU6-4Mawms0mtQFWR0iriSTr20qsjmaq-8--36sDTAAvR-Tr637-BSwedaYt2sjv5s2t0isPRhUuL7uiDW5is2A8tb0DfjtAjR0d9NPWOkz3pxPocaifpGfO53yHROidgJwkdMD4O8vA2EgijKeVtyT-9so_Rh0bujw-QGtjTBnwJnSTiaLtedwjS_Bl6Wns2VmCkeY56m_IFej_LrUpFrXhidVTUalTUalT0JcovwvkosuvqHPbGId7OdjjmRHlCrbTd1zvomKaTwuFK4tLFpZB4JRUpicDgJVBgRbo42soXbCWppO4rdLz9vlWvkSWHWA6XRHJgo8RRkgklfOW5S-b5vivLE7Qw8hXXJgVL8e9APUHnsGSFWOsW3KEqNKsBpcDbXDo8_Y-f_QY90e-gieidoePdza06B467W76tVOw3W6ad2g
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=RU+28965+IN+SUPERFICIAL+PYOGENIC+DISEASES&rft.jtitle=CHEMOTHERAPY&rft.au=SOMA%2C+YOSHINAO&rft.au=OGAWA%2C+KIMIKO&rft.au=YUN%2C+KOICHI&rft.au=YUN%2C+SHUKUKA&rft.date=1988&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=0009-3165&rft.eissn=1884-5894&rft.volume=36&rft.issue=Supplement4&rft.spage=534&rft.epage=537&rft_id=info:doi/10.11250%2Fchemotherapy1953.36.Supplement4_534&rft.externalDocID=article_chemotherapy1953_36_Supplement4_36_Supplement4_534_article_char_en
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-3165&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-3165&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-3165&client=summon